Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies- Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin)
Abstract
Authors
S Walzer S Era A Profico M Canciani M Farina C Ponzetti